Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 2
2015 3
2016 4
2017 7
2018 3
2019 2
2021 4
2022 6
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Results by year

Filters applied: . Clear all
Page 1
Genetic and methylation profiles distinguish benign, malignant and spitzoid melanocytic tumors.
Zaremba A, Jansen P, Murali R, Mayakonda A, Riedel A, Philip M, Rose C, Schaller J, Müller H, Kutzner H, Möller I, Stadtler N, Kretz J, Sucker A, Bankfalvi A, Livingstone E, Zimmer L, Horn S, Paschen A, Plass C, Schadendorf D, Hadaschik E, Lutsik P, Griewank K. Zaremba A, et al. Among authors: moller i. Int J Cancer. 2022 Nov 1;151(9):1542-1554. doi: 10.1002/ijc.34187. Epub 2022 Jul 11. Int J Cancer. 2022. PMID: 35737508 Free PMC article.
Genetic characterization of advanced conjunctival melanoma and response to systemic treatment.
Lodde GC, Jansen P, Möller I, Sucker A, Hassel JC, Forschner A, Eckardt J, Meier F, Reinhardt L, Kähler KC, Ziemer M, Schlaak M, Rahimi F, Schatton K, Meiss F, Gutzmer R, Pföhler C, Terheyden P, Schilling B, Sachse M, Heppt MV, Sindrilaru A, Leiter U, Zaremba A, Thielmann CM, Ugurel S, Zimmer L, Hadaschik E, Bechrakis NE, Schadendorf D, Westekemper H, Livingstone E, Griewank KG; German Dermatologic Cooperative Oncology Group (DeCOG, committee ocular melanoma). Lodde GC, et al. Among authors: moller i. Eur J Cancer. 2022 May;166:60-72. doi: 10.1016/j.ejca.2022.01.008. Epub 2022 Mar 10. Eur J Cancer. 2022. PMID: 35279471
Genetic and Methylation Analysis of CTNNB1 in Benign and Malignant Melanocytic Lesions.
Zaremba A, Jansen P, Murali R, Mayakonda A, Riedel A, Krahl D, Burkhardt H, John S, Géraud C, Philip M, Kretz J, Möller I, Stadtler N, Sucker A, Paschen A, Ugurel S, Zimmer L, Livingstone E, Horn S, Plass C, Schadendorf D, Hadaschik E, Lutsik P, Griewank K. Zaremba A, et al. Among authors: moller i. Cancers (Basel). 2022 Aug 23;14(17):4066. doi: 10.3390/cancers14174066. Cancers (Basel). 2022. PMID: 36077603 Free PMC article.
Intraventricular melanocytoma diagnosis confirmed by gene mutation profile.
Knappe UJ, Tischoff I, Tannapfel A, Reinbold WD, Möller I, Sucker A, Schadendorf D, Griewank KG, van de Nes JAP. Knappe UJ, et al. Among authors: moller i. Neuropathology. 2018 Jun;38(3):288-292. doi: 10.1111/neup.12443. Epub 2017 Dec 11. Neuropathology. 2018. PMID: 29226425
Clinical and genetic analysis of melanomas arising in acral sites.
Zaremba A, Murali R, Jansen P, Möller I, Sucker A, Paschen A, Zimmer L, Livingstone E, Brinker TJ, Hadaschik E, Franklin C, Roesch A, Ugurel S, Schadendorf D, Griewank KG, Cosgarea I. Zaremba A, et al. Among authors: moller i. Eur J Cancer. 2019 Sep;119:66-76. doi: 10.1016/j.ejca.2019.07.008. Epub 2019 Aug 14. Eur J Cancer. 2019. PMID: 31419753 Free PMC article.
SF3B1 and BAP1 mutations in blue nevus-like melanoma.
Griewank KG, Müller H, Jackett LA, Emberger M, Möller I, van de Nes JA, Zimmer L, Livingstone E, Wiesner T, Scholz SL, Cosgarea I, Sucker A, Schimming T, Hillen U, Schilling B, Paschen A, Reis H, Mentzel T, Kutzner H, Rütten A, Murali R, Scolyer RA, Schadendorf D. Griewank KG, et al. Among authors: moller i. Mod Pathol. 2017 Jul;30(7):928-939. doi: 10.1038/modpathol.2017.23. Epub 2017 Apr 14. Mod Pathol. 2017. PMID: 28409567 Free PMC article.
Genetic and Clinical Characteristics of ARID1A Mutated Melanoma Reveal High Tumor Mutational Load without Implications on Patient Survival.
Thielmann CM, Matull J, Roth S, Placke JM, Chorti E, Zaremba A, Lodde G, Jansen P, Krefting F, Kretz J, Möller I, Sucker A, Paschen A, Livingstone E, Zimmer L, Ugurel S, Schadendorf D, Hadaschik E, Griewank KG. Thielmann CM, et al. Among authors: moller i. Cancers (Basel). 2022 Apr 22;14(9):2090. doi: 10.3390/cancers14092090. Cancers (Basel). 2022. PMID: 35565222 Free PMC article.
Activating CYSLTR2 and PLCB4 Mutations in Primary Leptomeningeal Melanocytic Tumors.
van de Nes JAP, Koelsche C, Gessi M, Möller I, Sucker A, Scolyer RA, Buckland ME, Pietsch T, Murali R, Schadendorf D, Griewank KG. van de Nes JAP, et al. Among authors: moller i. J Invest Dermatol. 2017 Sep;137(9):2033-2035. doi: 10.1016/j.jid.2017.04.022. Epub 2017 May 10. J Invest Dermatol. 2017. PMID: 28499758 Free PMC article. No abstract available.
TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapy.
Thielmann CM, Matull J, Zaremba A, Murali R, Chorti E, Lodde G, Jansen P, Herbst R, Terheyden P, Utikal J, Pföhler C, Ulrich J, Kreuter A, Mohr P, Gutzmer R, Meier F, Dippel E, Weichenthal M, Kretz J, Möller I, Sucker A, Paschen A, Livingstone E, Zimmer L, Hadaschik E, Ugurel S, Schadendorf D, Griewank KG. Thielmann CM, et al. Among authors: moller i. Eur J Cancer. 2022 Jan;161:99-107. doi: 10.1016/j.ejca.2021.11.009. Epub 2021 Dec 20. Eur J Cancer. 2022. PMID: 34936949 Free PMC article.
28 results